logo-loader
viewOncoSenX

OncoSenX targeting solid tumors with its unique technology

OncoSenX Inc CEO Matthew Scholz sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The late stage pre-clinical cancer company, based in Seattle, Washington, targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

KORE Mining is cashed up and ready for exploration on 4 unique projects

KORE Mining (CVE: KORE) CEO Scott Trebilcock joined Steve Darling from Proactive to discuss the company, that is exploring 4 properties including their Imperial project which they just completed a positive PEA. Trebilcock tells Proactive about that gold project and also about their...

1 day, 23 hours ago

2 min read